CETP rs7082117: Understanding the TaqIB Variant and HDL Levels
The rs7082117 variant, commonly referred to as the TaqIB polymorphism, is a genetic change located within the CETP gene. It is widely studied for its association with varying levels of high-density lipoprotein (HDL) cholesterol in the blood.
What each genotype means
Higher HDL cholesterol levels
You carry two copies of the A allele (conventionally designated the B2 allele of the TaqIB restriction fragment polymorphism). In scientific studies, this genotype is consistently associated with reduced CETP protein activity and moderately higher baseline levels of circulating HDL cholesterol. However, evidence that this genotype directly reduces coronary heart disease risk remains mixed, as genetically elevated HDL does not always translate to improved vascular protection.
Carried by approximately 16% to 22% of individuals in European and Asian populations.
Intermediate HDL cholesterol levels
You carry one copy of the A (B2) allele and one copy of the G (B1) allele. Research shows that heterozygous carriers tend to have intermediate CETP activity and intermediate HDL cholesterol levels compared to individuals with the homozygous genotypes. The clinical significance regarding cardiovascular disease risk is modest and highly contingent on broader lifestyle and overall lipid profiles.
Carried by roughly 45% to 50% of individuals across European and Asian ancestries.
Typical HDL cholesterol levels
You carry two copies of the G allele (traditionally designated the B1 allele of the TaqIB polymorphism). This genotype is associated with standard or higher CETP activity and generally lower baseline HDL cholesterol levels relative to carriers of the A allele. These observed differences reflect population-level statistical associations and are not a clinical diagnosis of lipid disorders.
Carried by approximately 30% to 38% of individuals in European and Asian populations.
What is the rs7082117 Variant?
The rs7082117 variant is a single nucleotide polymorphism (SNP) situated within the CETP gene, which provides instructions for making the cholesteryl ester transfer protein. In scientific literature, this specific variant is frequently identified as the TaqIB polymorphism. It is a well-documented genetic marker that has been the subject of extensive research regarding lipid metabolism. Because it is located in a region of the gene that can influence how the protein is expressed or processed, researchers have long investigated whether this change alters the body's ability to manage cholesterol. While it is a common variant, it is important to understand that it represents only one small piece of the complex genetic puzzle that influences an individual's lipid profile and overall cardiovascular health.
The Role of the CETP Gene
The CETP gene encodes the cholesteryl ester transfer protein, which plays a critical role in lipid metabolism. This protein facilitates the transfer of cholesteryl esters from high-density lipoprotein (HDL) particles to other lipoproteins, such as low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL). By moving these fats, CETP effectively lowers the amount of cholesterol carried by HDL, often referred to as 'good' cholesterol. When CETP activity is reduced, it can lead to higher circulating levels of HDL-cholesterol. Because of this mechanism, the CETP gene has been a major target for pharmaceutical research aimed at modulating cholesterol levels. Understanding how genetic variants like rs7082117 affect the function or quantity of this protein helps scientists better understand the biological pathways that regulate cholesterol transport in the human body.
Research Associations and Evidence
Research into rs7082117 has consistently shown an association with HDL-cholesterol levels, where the B2 allele is linked to higher HDL-C. However, the clinical significance of this association remains a subject of debate. While some studies suggest that lower CETP activity might be protective, other research has produced conflicting results regarding its impact on coronary artery disease (CAD) risk. For instance, some studies have even suggested that in patients already treated with statins, certain CETP genotypes might be associated with different long-term cardiovascular outcomes. Because the evidence is mixed and often dependent on specific populations or existing medical conditions, the clinical utility of testing for this variant is limited. It is not currently used as a standard diagnostic tool for predicting heart disease risk, and any concerns regarding cholesterol management should always be discussed with a qualified healthcare provider.
Population Frequency and Interpretation
The rs7082117 variant is relatively common, with a minor allele frequency typically reported between 0.40 and 0.45 across various European and Asian populations. This high frequency means that a large portion of the population carries at least one copy of the variant. When interpreting genetic information, it is essential to remember that a statistical association observed in a large study does not necessarily predict an individual's health outcome. Genetic factors interact with diet, lifestyle, and other environmental influences to determine cholesterol levels. Therefore, individuals should not use this information to make assumptions about their personal health or to alter any prescribed medical treatments. Always consult with a physician or pharmacist before making changes to your health regimen based on genetic data.
How common is this variant?
The rs7082117 variant is common, with a minor allele frequency of approximately 0.40 to 0.45 across European and Asian populations.
Frequently asked questions
Does the rs7082117 variant cause heart disease?
No, this variant does not cause heart disease. While it is associated with changes in HDL-cholesterol levels, the link between this specific genetic change and the actual risk of developing cardiovascular disease is complex and remains a subject of ongoing scientific research.
Should I get tested for the CETP TaqIB variant?
There is currently no clinical recommendation for routine testing of this variant. Because the evidence regarding its impact on health is mixed, it is not used to guide standard medical care or heart disease prevention strategies.
Can I change my CETP activity through diet?
While diet and lifestyle significantly influence cholesterol levels, there is no evidence that you can specifically target or change the activity of the CETP protein through diet alone. Focus on heart-healthy habits recommended by your doctor, such as a balanced diet and regular exercise.
How does this variant affect my statin medication?
Some research suggests that genetic variation in CETP might influence how individuals respond to statin therapy, but these findings are not definitive. You should never adjust your medication based on genetic information without first consulting your prescribing physician or pharmacist.
Sources & further reading
Educational information only, last refreshed 10/12/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs7082117?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CETP
CETP promoter variant associated with preserved cognitive function, elevated HDL levels, and exceptional longevity across European cohorts.
The missense variant p.Ile422Val (I405V) in CETP is associated with reduced cholesteryl ester transfer protein activity, leading to elevated HDL-C levels and modest protection against coronary artery disease.
The I405V variant in CETP is associated with altered HDL cholesterol levels and cardiovascular risk profiles.
Well-established regulatory intronic polymorphism modulating cholesteryl ester transfer protein activity and circulating HDL cholesterol levels.
Known as the CETP TaqIB polymorphism, this intron variant is linked to reduced CETP activity, higher circulating HDL-C, and altered cardiovascular risk profile.
The I405V coding variant in cholesteryl ester transfer protein correlates with diminished CETP mass, elevated HDL cholesterol levels, and potential longevity benefits.